HTML has links - PDF has Authentication

Chapter 182-540 WAC

|Show DispositionsLast Update: 6/29/23

KIDNEY DISEASE PROGRAM AND KIDNEY CENTER SERVICES

WAC Sections

KIDNEY DISEASE PROGRAM (STATE-FUNDED)
HTMLPDF182-540-001Purpose.
HTMLPDF182-540-005Kidney disease program (KDP)—Definitions.
HTMLPDF182-540-015Kidney disease program (KDP)—General eligibility criteria.
HTMLPDF182-540-021Kidney disease program (KDP)—Household size.
HTMLPDF182-540-022Kidney disease program (KDP)—Income eligibility.
HTMLPDF182-540-023Kidney disease program (KDP)—Change of circumstances.
HTMLPDF182-540-025Kidney disease program (KDP)—Application and recertification requirements—KDP contractor.
HTMLPDF182-540-026Kidney disease program (KDP)—Application and recertification requirements—Client.
HTMLPDF182-540-030Kidney disease program (KDP)—Resource eligibility.
HTMLPDF182-540-045Kidney disease program (KDP) contractor requirements.
HTMLPDF182-540-055Kidney disease program (KDP) covered services.
HTMLPDF182-540-060Kidney disease program (KDP) client appeal rights.
HTMLPDF182-540-065Kidney disease program (KDP)—Reimbursement.
KIDNEY CENTER SERVICES
HTMLPDF182-540-101Purpose and scope.
HTMLPDF182-540-105Definitions.
HTMLPDF182-540-110Eligibility.
HTMLPDF182-540-120Provider requirements.
HTMLPDF182-540-130Covered services.
HTMLPDF182-540-140Noncovered services.
HTMLPDF182-540-150Reimbursement—General.
HTMLPDF182-540-160Items and services included in the composite rate.
HTMLPDF182-540-170Items and services not included in the composite rate.
HTMLPDF182-540-180Laboratory services.
HTMLPDF182-540-190Blood products and services.
HTMLPDF182-540-200Epoetin alpha (EPO) therapy.
HTMLPDF182-540-210Injectable drugs given in the kidney center.
Site Contents
Selected content listed in alphabetical order under each group